Literature DB >> 7579812

Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura.

M Ramael1, J Van den Bossche, C Buysse, I Deblier, K Segers, E Van Marck.   

Abstract

We studied immunoreactivity for c-fos protein and c-myc protein in malignant mesothelioma (36 cases) and non-neoplastic pleural mesothelium (45 cases) using the murine monoclonal antibodies 14E10 and 6E10. All malignant mesotheliomas and cases with non-neoplastic mesothelium exhibited not only nuclear but also cytoplasmic immunoreactivity for c-fos and c-myc protein in the majority of mesothelial cells. There was no statistically significant difference between the various mesothelioma subtypes or between neoplastic and non-neoplastic mesothelium for c-fos protein immunoreactivity (p > 0.05). There was statistically significant difference between neoplastic and non-neoplastic mesothelium for c-myc protein immunoreactivity (p < 0.01). We conclude that immunoreactivity for c-fos and c-myc protein is present in both non-neoplastic and neoplastic mesothelium, but that a higher proportion of neoplastic mesothelial cells are immunoreactive for c-myc protein when compared with non-neoplastic mesothelium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579812

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  5 in total

1.  Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.

Authors:  Atsushi Kitamura; Kazuyuki Matsushita; Yuichi Takiguchi; Hideaki Shimada; Yuji Tada; Makako Yamanaka; Kenzo Hiroshima; Masatoshi Tagawa; Takeshi Tomonaga; Hisahiro Matsubara; Makoto Inoue; Mamoru Hasegawa; Yasunori Sato; David Levens; Koichiro Tatsumi; Fumio Nomura
Journal:  Cancer Sci       Date:  2011-05-09       Impact factor: 6.716

2.  Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.

Authors:  Yinfei Tan; Eleonora Sementino; Jonathan Chernoff; Joseph R Testa
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

3.  Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.

Authors:  Arti Shukla; Jedd M Hillegass; Maximilian B MacPherson; Stacie L Beuschel; Pamela M Vacek; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Mol Cancer       Date:  2010-12-15       Impact factor: 27.401

4.  Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma.

Authors:  Iacopo Gesmundo; Francesca Pedrolli; Nicoletta Vitale; Alessia Bertoldo; Giulia Orlando; Dana Banfi; Giuseppina Granato; Ramesh Kasarla; Federico Balzola; Silvia Deaglio; Renzhi Cai; Wei Sha; Mauro Papotti; Ezio Ghigo; Andrew V Schally; Riccarda Granata
Journal:  Int J Mol Sci       Date:  2022-09-24       Impact factor: 6.208

5.  CELLFOOD™ induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways.

Authors:  Barbara Nuvoli; Raffaela Santoro; Simona Catalani; Serafina Battistelli; Serena Benedetti; Franco Canestrari; Rossella Galati
Journal:  J Exp Clin Cancer Res       Date:  2014-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.